Molgramostim inhalation for autoimmune pulmonary alveolar proteinosis
NIHR HSRIC
Record ID 32016001037
English
Authors' recommendations:
Molgramostim inhalation is a new drug to treat autoimmune pulmonary alveolar proteinosis (PAP). Autoimmune PAP is a rare lung disease that causes a build-up of protein material in the air sacs of the lungs, making it difficult to breath. Molgramostim inhalation is breathed in and works by altering the body's immune response, helping to prevent the build-up of protein in the lungs.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/molgramostim-inhalation-for-autoimmune-pulmonary-alveolar-proteinosis/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Administration, Inhalation
- Autoimmune Diseases
- Granulocyte-Macrophage Colony-Stimulating Factor
- Pulmonary Alveolar Proteinosis
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.